Moore A, Yust-Katz S, Icht O, et al. - This multicenter retrospective study was conducted to test bevacizumab’s efficacy and safety for stereotactic radiosurgery (SRS)-induced radiation necrosis (RN) in non-small cell lung cancer (NSCLC) patients treated with immune check-point inhibitors (ICI). Researchers analyzed 13 NSCLC patients managed with ICI, who received bevacizumab for post-SRS RN between April 2017 and June 2020. In 11 patients (85%), there was improvement in RN-associated symptoms. Reduction in daily dose of dexamethasone was implemented in ten patients (77%). All cases available for radiological assessment exhibited radiological improvement of RN. In this first series to report on the use of bevacizumab in this clinical scenario, findings showed that bevacizumab treatment seemed to be a safe as well as effective option for treating SRS-induced RN in patients with NSCLC managed with ICI.